BiotechTube
BetaGlue Therapeutics

BetaGlue Therapeutics

Milan, Italy· Est.
betaglue.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

BetaGlue Therapeutics is a clinical-stage radiopharmaceutical company developing YntraDose, a novel Yttrium-90 microsphere-based radiotherapy platform for the localized treatment of solid tumors. The company is initially targeting difficult-to-treat cancers like unresectable locally advanced pancreatic cancer (uLA-PDAC), with active clinical trials underway in Europe. Led by an experienced team with backgrounds in biotech, medtech, and nuclear medicine, BetaGlue aims to establish a new, more accessible standard of care in interventional oncology by combining biotechnology, nuclear science, and minimally invasive procedures.

OncologyPancreatic CancerSolid Tumors

Technology Platform

YntraDose: A proprietary Yttrium-90 microsphere-based radiotherapy platform designed for localized, intratumoral injection via an interventional oncology procedure. It combines a radioactive isotope with a delivery system ("glue") to retain radiation at the tumor site.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The growing radiopharmaceuticals market and high unmet need in solid tumors like pancreatic cancer present a major opportunity.
YntraDose's interventional approach could offer a more accessible and cost-effective alternative to complex external beam radiotherapy, potentially expanding treatment availability.
The platform's versatility allows for expansion into multiple high-prevalence cancer types (liver, breast).

Risk Factors

Clinical development risk is paramount, as trials may fail to show sufficient efficacy or safety.
The company faces intense competition from large pharma in radiopharmaceuticals and other pancreatic cancer therapies.
Regulatory hurdles for a novel device-drug combination and future funding needs present significant execution risks.

Competitive Landscape

BetaGlue competes in the targeted radiotherapy space against large players like Novartis (Pluvicto, Lutathera) and Bayer (Xofigo), though their approaches are systemic. More direct competitors include other companies developing localized radioembolization or brachytherapy solutions for solid tumors. It also competes with advanced external beam radiotherapy technologies (SBRT, PBRT) and other interventional oncology modalities.

More companies in Radiopharmaceuticals →More companies in Italy →